Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

m6A eraser FTO modulates autophagy by targeting SQSTM1/P62 in the prevention of canagliflozin against renal fibrosis
Youjing Yang, Qianmin Li, Yi Ling, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

The tumor-intrinsic role of the m 6 A reader YTHDF2 in regulating immune evasion
Sai Jin Xiao, Shoubao Ma, Baofa Sun, et al.
Science Immunology (2024) Vol. 9, Iss. 95
Open Access | Times Cited: 13
Fat mass and obesity associated protein inhibits neuronal ferroptosis via the FYN/Drp1 axis and alleviate cerebral ischemia/reperfusion injury
Yi Zhang, Xin Gong
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 3
Open Access | Times Cited: 11
MAGL protects against renal fibrosis through inhibiting tubular cell lipotoxicity
Shan Zhou, Xian Ling, Jielin Zhu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1583-1601
Open Access | Times Cited: 9
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Jun-Pei Hu, Jianhui Teng, Shan Hui, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29486-e29486
Open Access | Times Cited: 5
N6-methyladenosine (m6A) RNA modification in fibrosis and collagen-related diseases
Man Tan, Siyi Liu, Lubin Liu
Clinical Epigenetics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side
Aly M. Abdelrahman, Alaa S. Awad, Emaad M. Abdel‐Rahman
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 956-956
Open Access | Times Cited: 4
Cellular and Mitochondrial Pathways Contribute to SGLT2 Inhibitors-mediated Tissue Protection: Experimental and Clinical Data
Raúl Sanz, Sebastián García Menéndez, Felipe Inserra, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 13, pp. 969-974
Closed Access | Times Cited: 4
N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential
Yuting Sun, De Jin, Ziwei Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2023) Vol. 1866, Iss. 4, pp. 194967-194967
Open Access | Times Cited: 10
m6A RNA modification pathway: orchestrating fibrotic mechanisms across multiple organs
Xiangfei Huang, Zilu Yu, Juan Tian, et al.
Briefings in Functional Genomics (2025) Vol. 24
Closed Access
M6A Demethyltransferase FTO Attenuates Meniscus Degeneration and Osteoarthritis via Orchestrating Autophagy and Energetic Metabolism
Zongrui Jiang, Chengyun Zhang, Ruonan Liu, et al.
Advanced Science (2025)
Open Access
Natural products in traditional Chinese medicine for renal fibrosis: a comprehensive review
Qianqian Zhao, Meihua Jin, Qiang Zhao, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
m6A-mediated regulation of ECA39 promotes renal fibrosis in chronic kidney disease by enhancing glycolysis and epithelial-mesenchymal transition
Ziyuan Tong, Hainan Zhao, Chen Cui, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2025) Vol. 1872, Iss. 6, pp. 119981-119981
Closed Access
The role of N-methyladenosine modification in acute and chronic kidney diseases
Saiqi Qi, Jie Song, Linjun Chen, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 9
Emerging role of m6A modification in fibrotic diseases and its potential therapeutic effect
Wufei Ye, Xiongwen Lv, Songsen Gao, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115873-115873
Closed Access | Times Cited: 8
Isoliensinine Attenuates Renal Fibrosis and Inhibits TGF-β1/Smad2/3 Signaling Pathway in Spontaneously Hypertensive Rats
Mengying Yao, Dawei Lian, Meizhu Wu, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 2749-2762
Open Access | Times Cited: 7
Increased m6A-RNA methylation and demethylase FTO suppression is associated with silica-induced pulmonary inflammation and fibrosis
Yunyi Xu, Liqun Wang, Rui Qian, et al.
Toxicology (2023) Vol. 500, pp. 153673-153673
Closed Access | Times Cited: 6
Sodium-glucose cotransporter-2 inhibitors protect tissues via cellular and mitochondrial pathways: Experimental and clinical evidence
Raúl Sanz, Sebastián García Menéndez, Felipe Inserra, et al.
World Journal of Experimental Medicine (2024) Vol. 14, Iss. 2
Open Access | Times Cited: 1
m6A modification in non-coding RNAs: Mechanisms and potential therapeutic implications in fibrosis
Yutong Zhou, Ni Jian, Canhua Jiang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117331-117331
Open Access | Times Cited: 1
m6A demethylase FTO transcriptionally activated by SP1 improves ischemia reperfusion‐triggered acute kidney injury by activating Ambra1/ULK1‐mediated autophagy
Yan Chen, Y H Liu, Weiping Tu, et al.
The FASEB Journal (2024) Vol. 38, Iss. 20
Open Access | Times Cited: 1
Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment
Yanjun Zhang, Lijuan Zhan, Jing Li, et al.
Aging (2023) Vol. 15, Iss. 9, pp. 3857-3889
Open Access | Times Cited: 3
Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms
Xingxing Zhuang, Tao Liu, Liangbing Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
RNA sequencing reveals the mechanism of FTO in inhibiting inflammation and excessive proliferation of lipopolysaccharide-induced human glomerular mesangial cells
Xingxing Zhuang, Tao Liu, Liangbing Wei, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 12, pp. 3835-3846
Closed Access | Times Cited: 2
Toma de posición. Efecto de los iSGLT-2 sobre la presión arterial, el daño vascular, la enfermedad renal y el riesgo cardiovascular asociado
Felipe Inserra, Ezequiel Forte, Alicia Elbert, et al.
Revista de la Sociedad Argentina de Diabetes (2023) Vol. 57, Iss. 3
Open Access | Times Cited: 1
SGLT-2 Inhibitors as Novel Treatments of Multiple Organ Fibrosis
Jun-Pei Hu, Shan Hui, Jianhui Teng, et al.
(2024)
Closed Access
m6A RNA methylation: The latent string-puller in fibrosis
Xinglan He, Bingsi Tang, Puyu Zou, et al.
Life Sciences (2024) Vol. 346, pp. 122644-122644
Closed Access
Page 1 - Next Page

Scroll to top